DepoMed (DEPO) Misses Q1 EPS by 14c; Guides FY15 Sales Above Views

DepoMed (NASDAQ: DEPO) reported Q1 EPS of ($0.13), $0.14 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $31.7 million versus the consensus estimate of $33.8 million.

DepoMed sees FY2015 revenue of $310-335 million, versus the consensus of $305.02 million.

For earnings history and earnings-related data on DepoMed (DEPO) click here.

You May Also Be Interested In

• VNET Group (VNET) Misses Q2 EPS by 164c
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Alpha Cognition Inc (ACOG) PT Raised to $20 at H.C. Wainwright